MARTHA WAFER: Open Payments
NPI 1619179421 · BOSSIER CITY, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$574 in 27 payments from 10 companies in 2025. Trend: 2023 $712 · 2024 $595 · 2025 $574
Food & beverage: $574
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 9 | $194 |
| Vanda Pharmaceuticals Inc. | 4 | $90 |
| Ardelyx, Inc. | 4 | $86 |
| Indivior Inc. | 3 | $72 |
| Amgen Inc. | 2 | $29 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $27 |
| GlaxoSmithKline, LLC. | 1 | $24 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
| Braeburn Inc. | 1 | $18 |
| E.R. Squibb & Sons, L.L.C. | 1 | $18 |
Products named: GEMTESA, FANAPT, IBSRELA, SUBLOCADE, OTEZLA, CAPLYTA, TRELEGY ELLIPTA, AIRSUPRA.
Industry payments across LA — which companies pay providers there.
